March 4, 2020
This document is linked to :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.684.0433
This document is linked to :
info:eu-repo/semantics/altIdentifier/pmid/32134221
This document is linked to :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
This document is linked to :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_24A64741D9AA9
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
L. Bretagne et al., « Controverses sur le dépistage et la prise en charge des dyslipidémies familiales en 2020 [Controversies concerning screening and treatment of primary dyslipidemias in 2020] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.684.0433
Familial dyslipidemia is rare compared to polygenetic causes. Nevertheless, it is important not to miss this diagnosis, as it is more strongly associated with an increased risk of early cardiovascular disease and scores for calculating cardiovascular risk are not valid in this population. Early detection and management based on lifestyle optimization and treatment of cardiovascular risk factors can delay the onset of cardiovascular complications and thus improve patients' quality of life. A LDL-Cholesterol of 4,9 mmol/l has recently been suggested as the cut-off for starting lipid lowering therapy, but remains controversial because the majority of people above this threshold do not have primary monogenic dyslipidemia. The age at which therapy should be initiated as well as the targets for treatment are also controversial.